Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination With Vandetanib.

Trial Profile

Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination With Vandetanib.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Vandetanib (Primary)
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Nov 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 27 Feb 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Actual patient number (65) and Celgene Corporation as trial company added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top